Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 25Neoplasm Metastasis 2Urogenital Neoplasms 1Sleep Initiation and Maintenance Disorders 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Oligometastatic Prostate Carcinoma 1Neoplasms by Site 1Neoplasms 1Neoadjuvant Therapy 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Male Urogenital Diseases 1Genital Neoplasms, Male 1Fatigue 1Depression 1Cancer Pain 1Advanced Prostate Cancer 1Adenocarcinoma 1

Interventions

famitinib 1enzalutamide 1apalutamide 1Prednisolone 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1Drug Therapy 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoadjuvant Therapy × Abiraterone Acetate × Clear all
NCT05406999 2022-08-16

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting
900 enrolled
Genitourinary

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡